- Home
- IONS vs STRL Comparison
IONS vs STRL Comparison
Compare IONS & STRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- STRL
- Stock Information
- Founded
- IONS 1989
- STRL 1955
- Country
- IONS United States
- STRL United States
- Employees
- IONS N/A
- STRL N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- STRL Military/Government/Technical
- Sector
- IONS Health Care
- STRL Industrials
- Exchange
- IONS Nasdaq
- STRL Nasdaq
- Market Cap
- IONS 4.6B
- STRL 3.8B
- IPO Year
- IONS 1991
- STRL N/A
- Fundamental
- Price
- IONS $28.40
- STRL $140.27
- Analyst Decision
- IONS Buy
- STRL Strong Buy
- Analyst Count
- IONS 18
- STRL 2
- Target Price
- IONS $57.00
- STRL $185.00
- AVG Volume (30 Days)
- IONS 2.0M
- STRL 1.2M
- Earning Date
- IONS 04-30-2025
- STRL 05-05-2025
- Dividend Yield
- IONS N/A
- STRL N/A
- EPS Growth
- IONS N/A
- STRL 86.26
- EPS
- IONS N/A
- STRL 8.27
- Revenue
- IONS $705,138,000.00
- STRL $2,115,756,000.00
- Revenue This Year
- IONS N/A
- STRL N/A
- Revenue Next Year
- IONS $25.80
- STRL $7.82
- P/E Ratio
- IONS N/A
- STRL $16.96
- Revenue Growth
- IONS N/A
- STRL 7.28
- 52 Week Low
- IONS $23.95
- STRL $93.50
- 52 Week High
- IONS $52.34
- STRL $206.07
- Technical
- Relative Strength Index (RSI)
- IONS 44.54
- STRL 61.36
- Support Level
- IONS $27.57
- STRL $136.65
- Resistance Level
- IONS $29.04
- STRL $149.00
- Average True Range (ATR)
- IONS 1.79
- STRL 8.96
- MACD
- IONS 0.12
- STRL 3.24
- Stochastic Oscillator
- IONS 68.15
- STRL 83.42
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About STRL Sterling Infrastructure Inc.
Sterling Infrastructure Inc is a construction company that specializes in heavy civil infrastructure construction and infrastructure rehabilitation as well as residential construction projects. The company operates in three reportable segments namely, Transportation Solutions, E-Infrastructure Solutions, and Building Solution. Transportation Solutions include highways, roads, bridges, airfields, ports, light rail, and others. Building Solution projects include concrete foundations for single-family homes. E-Infrastructure Solutions include the services which are provided to large, blue-chip companies in the e-commerce, data center, distribution center, and warehousing, energy, mixed-use, and multi-family sectors. The majority of the revenue is generated from E-Infrastructure Solutions. .